Tegaserod

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Symptomatic Gastroespohageal Reflux Disease

Conditions

Symptomatic Gastroespohageal Reflux Disease

Trial Timeline

Jan 1, 2004 → Jun 1, 2005

NCT ID

NCT00149851

About Tegaserod

Tegaserod is a phase 2 stage product being developed by Novartis for Symptomatic Gastroespohageal Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00149851. Target conditions include Symptomatic Gastroespohageal Reflux Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00511771	Pre-clinical	Completed	—	—	Irritable Bowel Syndrome With Constipation
NCT00414024	Phase 3	Terminated	Feb 1, 2007	May 1, 2007	Opioid-induced Constipation
NCT00390975	Approved	Terminated	Jan 1, 2007	Mar 1, 2007	Gastroparesis
NCT00399659	Phase 3	Terminated	Nov 1, 2006	Apr 1, 2007	Opioid-induced Constipation
NCT00365820	Phase 2/3	Terminated	Jul 1, 2006	Apr 1, 2007	Constipation
NCT00348634	Approved	Terminated	Jul 1, 2006	Apr 1, 2007	Chronic Constipation
NCT00171457	Phase 3	Completed	Apr 1, 2005	Sep 1, 2006	Heartburn
NCT00171470	Phase 3	Completed	Apr 1, 2005	Aug 1, 2006	Dyspepsia
NCT00139568	Phase 3	Completed	Feb 1, 2005	Oct 1, 2005	Constipation
NCT00563758	Pre-clinical	Terminated	Dec 1, 2004	Feb 1, 2006	Constipation
NCT00563615	Pre-clinical	UNKNOWN	Nov 1, 2004	Oct 1, 2006	Constipation
NCT00171431	Phase 3	Terminated	Nov 1, 2004	May 1, 2006	Constipation Predominant
NCT00232037	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232102	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232089	Phase 3	Completed	May 1, 2004	Jun 1, 2006	Dyspepsia
NCT00142974	Phase 2	Terminated	May 1, 2004	Apr 1, 2005	Diabetic Gastropathy
NCT00142987	Approved	Completed	Apr 1, 2004	Jun 1, 2005	IBS-C and IBS With Mixed Bowel Habits
NCT00149877	Approved	Completed	Apr 1, 2004	Feb 1, 2006	Chronic Constipation
NCT00141089	Phase 3	Completed	Mar 1, 2004	Feb 1, 2005	Chronic Constipation
NCT00171483	Phase 3	Completed	Jan 1, 2004	Apr 1, 2005	Gastroesophageal Reflux Disease (GERD)

Competing Products

20 competing products in Symptomatic Gastroespohageal Reflux Disease

See all competitors

Product	Company	Stage	Hype Score
Sodium hyaluronate + placebo injection	Daiichi Sankyo	Phase 3	77
ISV-305	Sun Pharmaceutical	Phase 3	77
rabeprazole sodium + Placebo	Eisai	Phase 3	77
Verinurad + Febuxostat + Dapagliflozin	AstraZeneca	Phase 2	52
RDEA3170 + Febuxostat + Benzbromarone	AstraZeneca	Phase 1/2	41
Esomeprazole + Matching placebo	AstraZeneca	Phase 3	77
DFV890 + Placebo	Novartis	Phase 2	52
Omalizumab + Omalizumab + Placebo	Novartis	Phase 2	52
Pasireotide + Octreotide	Novartis	Phase 3	77
valsartan	Novartis	Approved	85
Atorvastatin - Cholestyramine - Sitosterol	Pfizer	Pre-clinical	22
Epoetin biosimilar	Pfizer	Pre-clinical	22
Apixaban + Standard of care	Pfizer	Phase 3	76
Azithromycin plus chloroquine	Pfizer	Phase 3	76
Mavacamten	Bristol Myers Squibb	Approved	84
Aficamten + Placebo	Sanofi	Phase 3	76
Vandetanib 300 mg	Sanofi	Pre-clinical	22
REGN7508 + Acetylsalicylic Acid (ASA) + Placebo	Regeneron Pharmaceuticals	Phase 3	76
Rivaroxaban + Placebo	Bayer	Phase 3	74
Droxidopa capsules + Placebo capsules	Lundbeck	Approved	82

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved